Sector News

Dassault dives into health tech, buying Medidata for $5.7 billion

June 17, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Dassault Systemes SE, a maker of industrial design software, agreed to buy Medidata Solutions Inc. for $5.7 billion to gain a foothold in the fast-growing market for clinical trial technology.

The deal pushes the French company further beyond its design roots into data processing and business analysis. Medidata’s software analyzes pharmaceutical and biotech trials for some of the world’s biggest drugmakers including Sanofi SA, Pfizer Inc. and AstraZeneca Plc.

“This is by far the largest acquisition we’ve ever made,” Pascal Daloz, chief financial officer of Dassault Systemes, said on a conference call. He said health is becoming a crucial market for the company, whose customers are mostly in aerospace, defense and consumer goods.

The all-cash deal values New York-based Medidata at $92.25 a share, 17% above its closing price on April 18, the last trading day before Bloomberg reported Dassault Systemes’ interest in the company. Medidata stock fell 4.4% to $90.60 in premarket trading.

Shares in Dassault Systemes, which has a market value of 36 billion euros ($41 billion) and annual sales of 3.5 billion euros last year, fell as much as 3% before recouping some of the decline to trade down 1% at 11:31 a.m. in Paris.

Personalized medicine
Medidata offers clients wearable sensors that help track patient health and biomarker analysis to select which patients may best respond to certain drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology, as the healthcare industry shifts towards personalized medicine and the targeting of individual patient profiles.

President Donald Trump’s protectionist trade agenda hasn’t reduced the appetite of European companies for U.S. takeovers. In fact their appeal has been growing, potentially turning the tables after years in which Europe was mostly a target for U.S. acquirers.

French advertising group Publicis Groupe SA announced its biggest ever takeover in April, a $4.4 billion deal for U.S.-based Alliance Data Systems Corp.’s digital marketing unit Epsilon.

The Medidata deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement. Dassault Systemes will finance it with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash. It’s the first time the French company has resorted to external funding, Daloz said.

By Geraldine Amiel, Marie Mawad and Bloomberg

Source: Fortune

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 15, 2019

Merck builds in CNS diseases with $576m Calporta buy

Life sciences

LinkedIn Twitter FacebookMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 […]

November 14, 2019

Longtime Abbott chief Miles White, designer of AbbVie spinoff, bows out of CEO job

Life sciences

LinkedIn Twitter FacebookAbbott Laboratories chief Miles White will shed the CEO title next year after a 21-year run and several major transformations at the global healthcare company. White will officially […]

November 14, 2019

Thermo Fisher looks to buy fellow diagnostics maker Qiagen: Bloomberg

Life sciences

LinkedIn Twitter FacebookThermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, which has the potential to become one of its largest acquisitions, according to a […]

Subscribe to our Weekly Newsletter

We're easy to reach